Allosteric binding sites on cell-surface receptors: novel targets for drug discovery
Top Cited Papers
- 1 March 2002
- journal article
- review article
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 1 (3) , 198-210
- https://doi.org/10.1038/nrd746
Abstract
Cell-surface receptors are the targets for more than 60% of current drugs. Traditionally, optimizing the interaction of lead molecules with the binding site for the endogenous agonist (orthosteric site) has been viewed as the best means of achieving selectivity of action. However, recent developments have highlighted the fact that drugs can interact with binding sites on the receptor molecule that are distinct from the orthosteric site, known as allosteric sites. Allosteric modulators could offer several advantages over orthosteric ligands, including greater selectivity and saturability of their effect.Keywords
This publication has 106 references indexed in Scilit:
- G Protein-Coupled Receptor Allosterism and ComplexingPharmacological Reviews, 2002
- Inverse, protean, and ligand‐selective agonism: matters of receptor conformationThe FASEB Journal, 2001
- Modeling the Functional Effects of Allosteric Modulators at Pharmacological Receptors: An Extension of the Two-State Model of Receptor ActivationMolecular Pharmacology, 2000
- Drug Discovery: A Historical PerspectiveScience, 2000
- Binding, gating, affinity and efficacy: The interpretation of structure‐activity relationships for agonists and of the effects of mutating receptorsBritish Journal of Pharmacology, 1998
- Proteins-Paradigms of complex systemsCellular and Molecular Life Sciences, 1995
- The Energy Landscapes and Motions of ProteinsScience, 1991
- Conformational Substates in ProteinsAnnual Review of Biophysics, 1988
- An allosteric model for benzodiazepine receptor functionBiochemical Pharmacology, 1983
- Croonian lecture.—On immunity with special reference to cell lifeProceedings of the Royal Society of London, 1900